You are here: Home » Companies » News
Business Standard

Zydus Cadila gets US FDA nod to market generic Abacavir for HIV treatment

The approval from the US FDA is for Abacavir and Lamivudine tablets USP in the strength of 600 mg/300 mg, Zydus Cadila said

Press Trust of India  |  New Delhi 

Zydus
Zydus

Drug firm Friday said it has received final approval from the US health regulator to market generic Abacavir and Lamivudine tablets used for treatment of a type of HIV infection.

The company also said in the regulatory filing that it had received final approval from the United States Food and Drug Administration (US FDA) to market generic Fondaparinux Sodium injection.

The approval from the US FDA is for Abacavir and Lamivudine tablets USP in the strength of 600 mg/300 mg, said.

The tablets are used with other antiretroviral medicines to treat human immunodeficiency virus-type 1 (HIV-1) infection that causes acquired immune deficiency syndrome (AIDS), it added.

"The product will be manufactured at the group's formulations manufacturing facility at special economic zone (SEZ), Ahmedabad," said.

The nod for the Fondaparinux Sodium injection USP is in the strengths of 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL and 10 mg/0.8 mL single-dose, it added.

Fondaparinux Injection is used to treat blood clots in deep veins and the lungs. It can also be used to prevent blood clots in patients undergoing certain types of surgeries, Zydus Cadila said.

"It will be manufactured at a partner's manufacturing site," it added.

The group now has more than 230 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 357.80 per scrip on BSE, down 0.54 per cent from their previous close.

First Published: Fri, November 16 2018. 13:35 IST
RECOMMENDED FOR YOU